Resource Summary Report

Generated by nidm-terms on Jul 28, 2026

U.S. Food and Drug Administration

RRID:SCR_012945
Type: Tool

Proper Citation

U.S. Food and Drug Administration (RRID:SCR_012945)

Resource Information

URL: http://www.fda.gov/

Proper Citation: U.S. Food and Drug Administration (RRID:SCR_012945)

Description: An agency of the United States Department of Health and Human Services, one of the United States federal executive departments that is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics and veterinary products. The FDA also enforces other laws, notably Section 361 of the Public Health Service Act and associated regulations, many of which are not directly related to food or drugs. These include sanitation requirements on interstate travel and control of disease on products ranging from certain household pets to sperm donation for assisted reproduction. (Wikipedia)

Abbreviations: FDA, USFDA

Synonyms: U.S. FDA, US FDA, US Food and Drug Administration, Food and Drug Administration, United States Food and Drug Administration

Resource Type: institution

Resource Name: U.S. Food and Drug Administration

Resource ID: SCR_012945

Alternate IDs: grid.417587.8, nlx_inv_1005074, ISNI: 0000 0001 2243 3366, Wikidata: Q204711, Crossref funder ID: 100000038

Alternate URLs: https://ror.org/034xvzb47

Record Creation Time: 20220129T080313+0000

Record Last Update: 20260725T190740+0000

Ratings and Alerts

No rating or validation information has been found for U.S. Food and Drug Administration.

No alerts have been found for U.S. Food and Drug Administration.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 1779 mentions in open access literature.

Listed below are recent publications. The full list is available at nidm-terms .

Luo M, et al. (2025) Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. Cancer discovery, 15(3), 511.

Cheng CH, et al. (2025) Artificial intelligence in cancer: applications, challenges, and future perspectives. Molecular cancer, 24(1), 274.

Birnkrant DJ, et al. (2025) A New Perspective on Drugs for Duchenne Muscular Dystrophy: Proposals for Better Respiratory Outcomes and Improved Regulatory Pathways. Paediatric drugs, 27(2), 143.

Glaviano A, et al. (2025) Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. Journal of hematology & oncology, 18(1), 6.

Patrinos GP, et al. (2025) Systematic analysis of the pharmacogenomics landscape towards clinical implementation of precision therapeutics in Greece. Human genomics, 19(1), 11.

Dutra Alves NS, et al. (2025) Advances in regenerative medicine-based approaches for skin regeneration and rejuvenation. Frontiers in bioengineering and biotechnology, 13, 1527854.

Yazdani A, et al. (2025) An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results. Scientific data, 12(1), 424.

Santigli E, et al. (2025) Seroprevalence of SARS-CoV-2 antibodies among oral health care workers with natural seroconversion: a systematic review and meta-analysis. Scientific reports, 15(1), 7848.

Shiraishi C, et al. (2025) Changes in the blood cyclosporine level after switching from voriconazole to isavuconazole in a patient with aplastic anemia: insights from physiologically based pharmacokinetic model simulation and the Adverse Event Reporting

System database study. Frontiers in microbiology, 16, 1525991.

Siebenhüner AR, et al. (2025) Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors. Endocrine-related cancer, 32(6).

Yamada D, et al. (2025) Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies. International journal of clinical oncology, 30(6), 1069.

Perfetto C, et al. (2025) Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer types. Cancer drug resistance (Alhambra, Calif.), 8, 14.

Chen S, et al. (2025) Sorafenib with or without co-interventions for hepatocellular carcinoma. The Cochrane database of systematic reviews, 6(6), CD015851.

Yang Y, et al. (2025) A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database. Frontiers in pharmacology, 16, 1510992.

Mandal K, et al. (2025) Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Molecular cancer, 24(1), 246.

Türkmen C, et al. (2025) Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysis. BMJ open, 15(10), e102696.

Mul K, et al. (2025) Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study. PloS one, 20(12), e0331163.

Pinna D, et al. (2025) Essential Oils and Cultural Heritage Conservation: Are They Safe, Environmentally Friendly, Sustainable, and Negligibly Toxic? Gels (Basel, Switzerland), 11(12).

Lin H, et al. (2025) Post-market safety profile of cefiderocol: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS). BMC pharmacology & toxicology, 26(1), 58.

De Brouchoven I, et al. (2025) Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome. Frontiers in pediatrics, 13, 1475143.